Day 2 – Thursday, 17 September 2025Wednesday, September 17, 2025 - ET (Eastern Time, GMT-05:00)

Major players in the tech space, with market caps orders of magnitude greater than traditional healthcare companies, are starting to make their move into the healthcare market. Could this transition provide a catalyst for growth within the healthcare sector? Our panel of big tech executives, and CEOs who have partnered with them, share their experiences from communicating and partnering with big tech.

• Strategies for engaging with big tech in the healthcare landscape
• How partnerships with big tech differ from traditional life science strategics
• Value provided by big tech to medtech companies

For medtech companies, reimbursement can prove the final hurdle before long-term commercial success. Yet, for many, the process is not considered early enough, leading to costly delays and additional investigations to prove value. Hear insights from CEOs, strategics and investors on successful reimbursement strategy among what may be a rapidly reformed CMS landscape.

• Potential for CMS reform and what it may mean
• Case studies in successful reimbursement strategy and the learnings newer companies can take
• Importance of considering reimbursement prior to regulatory approval

Founding a company is a daunting task, especially for first-time founders experiencing the highs and lows of entrepreneurship for the first time. We bring together investors and experienced medtech executives to discuss areas of commercialization which are often undervalued and neglected, and the value created by getting these aspects right.

• Areas which can often be overlooked by medtech founders
• The importance of having experience within the leadership team at a C-suite and board level
• Building for long-term success from day one

The USA has long been the first choice for life science commercialization, but where should companies go from there? With EUMDR creating uncertainty in Europe and increased interest in Asia and the Middle East, there is arguably more choice than ever before for global expansion. Our panel will delve in to the realities of global markets, strategies for getting there and how to know which market is best for your company.

• How to know when your company is ready for global expansion
• Finding partners and support in new markets
• Cultural and macroeconomic differences in different geographies and how they impact medtech

Medtech investment increased drastically between 2020 and 2021 in the height of the COVID-19 pandemic, riding the wave of increased investor interest and a wave of IPOs medtech valuations surged to unprecedented levels. These valuations naturally subsided through the lack of exits observed in the years since COVID, but with exits returning in the form of both IPOs and M&A investors are seeing real world examples of return on investments. Our panel of investors and medtech leaders discuss the future of valuations and expectations for investors and startups.

• The valuation correction and its impact
• What goes into a medtech company valuation
• Valuation expectations moving forward

The 2024 re-election of the Trump administration marked a pivotal moment for the life sciences industry, ushering in a wave of potential policy shifts. This panel will examine how the industry has navigated the first year of this administration, potential changes to drug pricing, and the evolving role of regulatory bodies.

The discussion will also delve into how companies are preparing for long-term impacts, addressing pressing questions around access, affordability, and the future of innovation. Attendees will gain insight into the strategies industry leaders are deploying to adapt to the shifting landscape, maintain patient safety, and continue delivering transformative therapies.

• Examining the repeal of key healthcare legislation and its effects on drug pricing, access, and market dynamics
• Analysing the evolving role of the FDA health policy
• Comparing US healthcare outcomes with global systems and addressing challenges in affordability and innovation
• Strategies and future outlook – Exploring how companies are navigating uncertainty, maintaining compliance, and driving innovation amidst political change

The field of neuroscience is experiencing a transformative era, with groundbreaking advancements reshaping how we understand and treat complex brain conditions. From revolutionary therapies in biopharma to cutting-edge medical devices and the integration of digital health solutions, innovation is unlocking new possibilities for addressing neurological disorders. This panel will bring together thought leaders from across life sciences to discuss how their respective industries are contributing to this progress, the challenges they face, and the opportunities for collaboration. As neuroscience remains a critical frontier in medicine, the panel will explore how these innovations are improving patient outcomes and paving the way for a future where brain health is prioritised like never before.

• The impact of AI, machine learning, and advanced imaging on accelerating neuroscience research and treatment development
• Leveraging genomics and biomarkers to create tailored approaches for neurological disorders
• Patient-centric innovation and prioritising patient needs through real-world data, digital tools, and collaborative care models
• Collaboration: Bridging biopharma, medtech, and digital health to drive unified solutions for brain health challenges